Characteristics of Patients With Sickle Cell Disease
Completed
Conditions studied: Sickle Cell Disease
In brief
This was a retrospective descriptive analysis of health care claims data using the IQVIA open source medical and pharmacy claims databases.
Key facts
- Study ID
- NCT05494541
- Run by
- Novartis Pharmaceuticals
- People needed
- 540
- Starts
- 2021-08-30
- Expected to finish
- 2021-10-27
- Last updated by the study team
- 2022-11-08
Who can join
Age: 16 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- At least 1 claim in IQVIA Patient Centric Medical Claims Database (Dx) with SCD diagnosis (ICD-10 D57.xx, except D57.3) within the study period;
- At least 1 claim for administration of crizanlizumab within the index period. Index date was the date of first administration;
- At least 1 claim with HCPCs for crizanlizumab (J0791) OR with at least one claim for an unspecified biologic (J3590) on the same day as a claim for SCD (ICD-10 D57.xx, except D57.3) OR with at least one claim with HCPCs C9053;
- At least 16 years of age on the index date;
- Linkage to the IQVIA Longitudinal Prescription Database (LRx) within the study period;
- Stability and eligibility in Dx during the 12 months prior to the index date;
- Stability and eligibility in LRx during the 12 months prior to the index date
You may not qualify if…
- None
Where it is running
- Novartis Investigative Site — East Hanover, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.